Bicycle Therapeutics (“Bicycle”) is pioneering a unique class of chemically synthesized medicines based on its proprietary bicyclic peptide (Bicycle®) product platform to address therapeutic needs unreachable with existing treatment modalities. Bicycles’ small size and exquisite targeting delivers rapid tumor penetration and retention while clearance rates and routes can be tuned to minimize exposure of healthy tissue and bystander toxicities. The company has entered into strategic partnerships with Biogen-spinout Bioverativ, AstraZeneca, and ThromboGenics.